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Abstract 
Surveillance studies of enhancing renal masses report on a mean tumor growth rate of about 0.3 cm/year. In most of 
these studies however, only small tumors in elderly patients were followed. In the current report, we attempt to evalu-
ate the growth rate of “clinically significant” renal carcinomas defined as tumors that were treated immediately upon 
diagnosis. 46 patients (mean age 64 years SD 11 years) were treated for renal carcinoma. All had a cross-sectional 
imaging studies performed 6–60 months prior to diagnosis of kidney cancer demonstrating no tumor. Tumor growth 
rate was calculated by dividing tumor’s largest diameter by the time interval between the normal kidney imaging and 
diagnosis of renal cancer. Mean tumor diameter was 4.5 cm (SD 2.4 cm). Mean time period from the normal imaging 
to diagnosis of renal cancer was 33.6 months (SD 18 months). According to the proposed model, the average growth 
rate of “clinically significant” renal carcinomas was 2.13 cm/year (SD 1.45, range 0.2–6.5 cm/year). Tumor growth rate 
correlated inversely with patient’s age (p = 0.007). Patient gender or Fuhrman’s grade did not correlate however. The 
growth rate of “clinically significant” renal cancer appears to be higher than the rate reported in surveillance trials. 
Renal tumors tend to grow faster in young patients. As such, variable growth rate should be taken into account when 
considering active surveillance in young patients and when designing trials for evaluation of anti-cancer agents.
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Background
The growth rate of solid tumors is an important param-
eter in understanding their biology, in designing neo-
adjuvant trials or when appreciating novel anti-cancer 
agents. The growth rate of “clinically significant” renal 
cancer is not well understood since patients with “sig-
nificant tumors” are often treated without delays (Cam-
bell et  al. 2007). Most of the literature on growth rates 
of renal tumors is driven from surveillance studies in 
patients with solid enhancing renal masses. These are 
usually small tumors in elderly patients and in many 
cases without histologic confirmation. Collectively, slow 
growth rate of 0.3 cm per year in the largest diameter is 
reported in most of these studies. A meta-analysis of 10 
manuscripts reporting on 234 patients with enhancing 
renal masses that were not treated upon diagnosis also 
demonstrated a small growth rate (Chawla et  al. 2006). 
In that study, mean patient age was 71  years (the Fox 
Chace Cancer Center experience only), mean lesion size 
at presentation was 2.6  cm and mean follow-up period 
was 30 months. The growth rate of renal masses in that 
study was 0.28  cm/year (range 0.09–0.86  cm/year). A 
somewhat faster growth rate was observed in the sub-
group of patients with pathologically confirmed renal 
cancer (0.4 cm/year, range 0.42–1.6 cm/year). In another 
large study by Jewett et al., a growth rate of 0.13 cm/year 
was reported (Jewett et  al. 2011), and even when larger 
tumors are being followed growth rate did not exceed 
0.6 cm/year (Mues et al. 2010; Mehrazin et al. 2014).
Unfortunately, generalizing the growth rate of renal 
tumors from studies of elderly, frail patients under active 
surveillance may be misleading. More specifically, these 
patients represent a selected population in which both 
the patient and the physician deem no significant survival 
impact by the renal tumor. Very few attempts have been 
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made to assess the growth rate of “clinically significant” 
malignant renal tumors. In a single study of 9 patients 
with renal imaging 6 months or more prior to the diag-
nosis of renal cancer demonstrating no tumor or a small 
tumor that was overlooked, Staehler et  al calculated an 
extremely high growth rate of 6.4 cm per year (Staehler 
et al. 2010). To better investigate this matter, we sought to 
evaluate a larger population of patients who were treated 
for renal cell carcinoma.
In this study we calculated growth rate of “clinically 
significant” renal tumors (that were treated shortly after 
diagnosis) using prior cross-sectional imaging study 
showing no renal mass.
Methods
Patients
A total of 435 patients underwent surgical treatment for 
renal cancer in our institution between January 1998 
and December 2013. In 46 patients (mean age 64 years, 
SD 11 years) previous cross-sectional imaging studies of 
the urinary system were done 6–60 months prior to the 
diagnosis of the renal cancer showing no evidence of kid-
ney cancer. Previous imaging studies included abdomi-
nal computerized tomography in 18 cases (10 with and 
8 without intravenous contrast injection) and renal 
ultrasonography in 28 cases. Institutional review board 
approval was obtained (#202-5.9.08).
Mean time interval between the imaging studies show-
ing no renal tumor and diagnosis of renal cancer was 
33.6  months (SD 18.2  months). In 13 cases (28.2  %), 
the imaging study showed another renal pathology 
(renal cysts in 9 cases, stones in 3 and atrophic kidney 
in 2 cases). In the rest of the patients, normal kidneys 
were demonstrated. All patients were operated shortly 
after diagnosis. Partial nephrectomy was performed 
on 24 patients, radical nephrectomy upon 20 and radi-
ofrequency percutaneous needle ablation in 2 patients. 
Median Post-operative follow-up was 68 months.
The pathological specimens were evaluated according 
to the 2002 version of the TNM classification (Greene 
et  al. 2002), the histologic subtyping according to the 
1997 UICC classification (Störkel et  al. 1997), and the 
grading according to Fuhrman’s nuclear grading system 
(Fuhrman et al. 1982). Grading of clear cell cancers was 
dichotomized to low (Fuhrman’s grades 1–2) and high 
(Fuhrman’s grades 3–4) grades.
Calculation of tumor growth rate
Calculation of tumor growth rate was based on two 
assumptions:
1. Macroscopic tumor growth commenced shortly after 
the normal imaging study.
2. Tumor growth was linear.
Annual tumor growth rate was calculated by divid-
ing tumor’s largest diameter measured on the diagnostic 
computerized tomography by the time interval between 
the normal imaging studies to diagnosis of kidney 
tumor. The dependency of the growth rate on the fol-
lowing parameters was studied: patient’s age and gender, 
type of previous imaging study showing normal kidney 
(ultrasonography or computerized tomography), Fuhr-
man’s grade (Grades 1–2 vs. grades 3–4) and recurrence 
(patient’s that developed tumor recurrence vs. patients 
that did not). A 2-tailed the Student’s t test and analysis 
of variance were used for comparing the variables and a 
p value <0.05 was considered statistically significant. The 
JMP software (SAS Institute Inc. Cary, NC, USA) was 
used for data processing.
Results
The growth rate of renal cancer was calculated in 46 
patients that had prior cross-sectional imaging study 
showing normal kidneys. Patients’ and tumors’ char-
acteristics are presented in Table 1. Several examples 
of imaging studies showing normal kidneys followed 
by imaging of the same patients showing kidney 
cancer are presented in Fig.  1. After a median post-
operative follow-up of 68 months, 5 patients (10.8 %) 
developed distant metastases. A total of 17 patients 
(36.9 %) died. In 3 patients (6.5 %) death was disease 
specific.
Based on the model, the average growth rate of kid-
ney tumors in the study was 2.13 cm/year (SD 1.45 cm/
year, range 0.2–6.5 cm/year). The effect of various param-
eters on tumor growth rate is presented in Table  2. 
Table 1 Baseline characteristics of the patients
a Patients with Fuhrman’s grade 2–3 were not included in the analysis
Characteristic
Mean patient age [years, (SD)] 64 (11)
Gender
 Male 29 (%)
 Female 17 (%)
Mean time from normal imaging to diagnosis [months (SD)] 33.6 (17.9)
Mean tumor’ largest diameter [cm, (SD)] 4.6 (2.5)
Histological type
 Clear cell 29 (63 %)
 Papillary 14 (30.4 %)
 Chromophobe 3 (6.5 %)
Fuhrman’s gradea
 1–2 14 (52 %)
 3–4 13 (48 %)
Page 3 of 5Gofrit et al. SpringerPlus  (2015) 4:580 
Figure  2 demonstrates that tumors’ growth rate cor-
relates inversely with patient’s age (p =  0.007). Patient’s 
gender, type of previous imaging showing normal kidney, 
Fuhrman’s grade and metastases development during fol-
low-up did not show significant correlation with growth 
rate.
Fig. 1 Computerized tomographic scans of selected patients. a A 52-year-old man, on October 2010 normal kidneys were found and on December 
2013, a 9 cm clear cell tumor with IVC invasion was found (growth rate 2.84 cm/year). b A 51 year-old-man, on August 2009 normal kidneys were 
found and on April 2013, 4.5 cm clear cell tumor was found (growth rate 1.23 cm/year). c A 45 year-old man on February 2006 normal kidneys were 
found and on November 2010, a 4 cm chromophobe carcinoma was found (growth rate 0.84 cm/year). d A 64-year-old lady that had left nephrec-
tomy on May 2009. CT done on October 2010 showed normal right kidney. On August 2011 the patient had a 2.8 cm clear cell carcinoma (growth 
rate 3.36 cm/year)
Table 2 Growth tumor rate according to patient’s and tumor’s characteristic
a Patients with Fuhrman’s grade 2–3 were not included in the analysis
Characteristic Number of patients Average growth rate (SD) cm/year P value
All patients 46 2.13 (1.45 cm) –
According tumor diameter 46 – 0.002
According to age 46 – 0.007
According to gender 0.97
 Males 17 2.14 (1.4)
 Females 29 2.15 (1.5)
According to type of imaging 0.197
 Ultrasonography 28 2.35 (1.7)
 CT 18 1.85 (0.9)
According to Fuhrman’s gradea 0.8
 1–2 14 2.4 (1.05)
 3–4 13 2.25 (1.65)
According to recurrence of tumor 0.5
 Yes 5 2.68 (2.15)
 No 41 2.05 (1.3)
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Discussion
Understanding the natural history of solid tumors 
requires knowledge of their growth kinetics. Most of the 
data on the growth kinetics of kidney tumors is driven 
from surveillance studies of small enhancing masses. 
The leading studies are presented in Table 3. The average 
growth rate in most studies has been observed at 0.3 cm/
year. When large tumors were followed, the growth rate 
was slightly higher (0.44–0.57 cm/year) (Mues et al. 2010; 
Mehrazin et al. 2014). In the current study, of younger, fit 
patients with pathologically confirmed cancer, the aver-
age growth rate was much larger at 2.13 cm/year.
How is it possible to explain this multiplicity? We 
believe that differences in population and in study design 
can explain the diversity. While patients in surveillance 
studies are often at their 8th and 9th decades (Chawla 
et  al. 2006; Mues et  al. 2010), mean patient’s age in the 
current study was 64 years. As seen in Fig. 2, renal cancer 
growth rate correlates inversely with patient’s age. There-
fore, a growth rate of a few millimeters per year may not 
apply to young patients.
Another explanation for the differences in growth rates 
between surveillance studies and the current study can 
be found in the Gompertzian model of tumor growth 
(Laird 1965). The model assumes an early exponential 
tumor growth followed by increasing retardation of the 
rate as the tumor matures and depletes its resources. This 
is reflected in a sigmoidal growth curve. While tumors in 
the current study were by definition in the early phase of 
their growth (proved by the normal imaging in the begin-
ning of the period), tumors in the surveillance studies 
were diagnosed in various phases of their growth, some 
if not most of them beyond the inflection of the growth 
curve, where tumor growth rate is very slow. Addition-
ally, a slow growth rate of tumors in surveillance studies 
is predicted by the length bias (Black and Welch 1993). 
Since most of the tumors reported in surveillance trials 
were diagnosed incidentally with cross-sectional imag-
ing, they are inherently slow growing tumors. Indeed, 
89 % of the tumors in the meta-analysis by Chawla et al. 
had histologic evaluation which demonstrated low grade, 
small tumors. (Cambell et al. 2007). In contrast, the “clin-
ically significant” tumors in the current study were much 
larger and half had a high Fuhrman grade.
Suggestions for much faster growth rates of “clinically 
significant” renal tumors can be identified in the pub-
lished literature. Staehler et al. reported on 9 patients that 
had kidney imaging 6 months or more prior to the diag-
nosis of renal cancer showing no tumor or a small tumor 
Fig. 2 Correlation between patient’s age and tumor growth rate
Table 3 Leading studies in surveillance of renal cell carcinoma and observational studies
a In some of the studies the median and not the mean are reported
Author Study type Number of patients Length of follow-up 
(months)a
Mean tumor diametera 
(cm)
Growth rate (cm/year)
Chawla et al. (2006) Surveillance study 234 34 2.6 0.28
Jewett et al. (2011) Surveillance study 127 29 2.1 0.13
Lee et al. (2008) Surveillance study 30 12.3 2.6 0.59
Abouassaly et al. (2008) Surveillance study 110 24 2.5 0.26
Crispen et al. (2008) Surveillance study 109 26 2 0.21
Mason et al. (2011) Surveillance study 82 36 2.3 0.25
Patel et al. (2012) Surveillance study 71 34 2.2 0.21
Li et al. (2012) Surveillance study 32 46 2.14 0.8
Brunocilla et al. (2014) Surveillance study 58 88.5 2.6 0.7
Mues et al. (2010) Surveillance study 36 36 7.13 0.57
Mehrazin et al. (2014) Surveillance study 65 38.9 4.9 0.44
Staehler et al. (2010) Observational study 9 14.6 2 6.4
Current study Observational study 46 33.6 4.6 2.13
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that was overlooked. They calculated an extremely high 
growth rate of 6.4 cm per year (Staehler et al. 2010). Oda 
et al. studied the growth rate of kidney cancer metasta-
ses and showed that it can reach 7.87 cm/year (Oda et al. 
2001).
Despite its merits, the current study has is not devoid 
of limitations. It is retrospective, small and single insti-
tutional series. The two assumptions used for calculating 
tumor’s growth rate are not based on literature. Assum-
ing that macroscopic tumor growth commenced shortly 
after the normal imaging however, is very conservative. 
If one was to hypothesize that the growth of the tumor 
began in the middle of the time period between the nor-
mal imaging and the diagnosis of the tumor would signif-
icantly increase the growth rate. Moreover, assuming that 
the growth is linear is certainly wrong, but considering 
the sigmoidal shape of the Gompertzian curve, the mid-
dle part of the curve is almost liner. Another concern is 
the combining of patients with initial normal ultrasonog-
raphy and initial normal CT. Both modalities however, 
are acceptable for diagnosis and follow-up of kidney can-
cer and patients that had initial CT or initial ultrasonog-
raphy had comparable cancer growth rates (Table 2).
Conclusions
The growth rate of “clinically significant” renal cancer 
appears to be greater than the rate reported from active 
surveillance studies of enhancing renal masses. Further 
investigation is warranted for renal lesion growth dynam-
ics, particularly for younger patients and those in neoad-
juvant or screening trials.
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